Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ceruletide for schizophrenia: a double-blind study.

J A Mattes, W Hom, J M Rochford

    Biological Psychiatry
    |May 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.

    Archives of general psychiatry·2000
    Same author

    Mood improvement from transcranial magnetic stimulation.

    The American journal of psychiatry·1999
    Same author

    Fluoxetine and norfluoxetine.

    The American journal of psychiatry·1998
    Same author

    Sertindole versus haloperidol for schizophrenia.

    The American journal of psychiatry·1998
    Same author

    Stroke resulting from a rapid switch from phenelzine to tranylcypromine.

    The Journal of clinical psychiatry·1998
    Same author

    Olanzapine on trial.

    The American journal of psychiatry·1998
    Same journal

    Neuroimaging of Heterogeneity in Neuropsychiatric Disorders: Toward Disease Progression Modeling.

    Biological psychiatry·2026
    Same journal

    Impact of Transcranial Direct Current Stimulation-Induced Electric Fields on Slowing Cognitive Decline in Older Adults With Mild Cognitive Impairment or Remitted Major Depressive Disorder: An Analysis of the PACt-MD Randomized Clinical Trial.

    Biological psychiatry·2026
    Same journal

    Remembering Jon-Kar Zubieta, M.D., Ph.D.

    Biological psychiatry·2026
    Same journal

    Kappa opioid receptor availability in borderline personality disorder: An in-vivo investigation with [<sup>11</sup>C]EKAP PET imaging.

    Biological psychiatry·2026
    Same journal

    From Satiety to Substance Use: Neural Mechanisms of GLP-1 Signaling in Appetite and Reward.

    Biological psychiatry·2026
    Same journal

    Distinct and Shared Molecular Mechanisms Underlie Morphological-Functional Overcoupling and Undercoupling in Major Depressive Disorder.

    Biological psychiatry·2026
    See all related articles

    This study found that ceruletide, a cholecystokinin analog, did not significantly benefit patients with chronic schizophrenia when used alongside standard neuroleptic treatment. Further research is needed to explore potential therapeutic roles.

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Pharmacology

    Background:

    • Ceruletide, a cholecystokinin (CCK) analog, exhibits neuroleptic-like activity in mice.
    • Previous open studies suggested potential benefits of ceruletide for schizophrenic patients.

    Purpose of the Study:

    • To evaluate the efficacy of ceruletide in treating chronic schizophrenic patients with residual symptoms.
    • To assess ceruletide's effectiveness as an adjunctive therapy to neuroleptics in a double-blind, placebo-controlled trial.

    Main Methods:

    • A double-blind, randomized study involving 17 chronic schizophrenic patients.
    • Patients received two intramuscular injections, one week apart, of either ceruletide (0.6 microgram/kg) or placebo, while continuing neuroleptic medication.
    • Evaluations included prognostic variables, Brief Psychiatric Rating Scale (BPRS), Symptom Checklist-90 (SCL-90), and global assessments by psychiatrists, patients, and relatives.

    Related Experiment Videos

    Main Results:

    • Few significant differences were observed between the ceruletide and placebo groups.
    • Any observed differences were equally likely to favor placebo as ceruletide.
    • No predictors of treatment benefit were identified among patients receiving ceruletide.

    Conclusions:

    • Ceruletide did not demonstrate significant efficacy as an adjunctive treatment for chronic schizophrenia with residual symptoms in this double-blind study.
    • The findings contrast with previous open-label observations, suggesting a need for further investigation into ceruletide's therapeutic potential and the reasons for negative results.